Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial

Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial

Background: The recent discovery that a combination of noradrenergic and antimuscarinic drugs improved upper airway muscle function during sleep and reduced OSA severity has revitalized interest in pharmacologic therapies for OSA. Research Question: Would 1 week of reboxetine plus oxybutynin (Reb-Ox...

Full description

Bibliographic Details
Main Authors: Azarbarzin, A. (Author), Lombardi, C. (Author), Marconi, M. (Author), Meriggi, P. (Author), Parati, G. (Author), Perger, E. (Author), Rosa, D. (Author), Sands, S.A (Author), Taranto Montemurro, L. (Author), Vicini, S. (Author), Wellman, A. (Author), Zanotti, L. (Author)
Format: Article
Language:English
Published: Elsevier Inc. 2022
Subjects:
adrenergic receptor affecting agent
Adrenergic Uptake Inhibitors
antimuscarinic and norepinephrine reuptake inhibitors
blood
combination drug therapy
controlled study
crossover procedure
Cross-Over Studies
double blind procedure
Double-Blind Method
Drug Therapy, Combination
female
Female
human
Humans
male
Male
mandelic acid derivative
Mandelic Acids
middle aged
Middle Aged
Muscarinic Antagonists
muscarinic receptor blocking agent
OSA
oxybutynin
pathophysiology
pharmacologic treatment
polysomnography
Polysomnography
randomized controlled trial
reboxetine
Reboxetine
severity of illness index
Severity of Illness Index
Sleep Apnea, Obstructive
sleep disordered breathing
treatment outcome
Treatment Outcome
upper airway
vigilance
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items